Lakewood-Amedex Biotherapeutics Inc. (NASDAQ:LABT) Short Interest Up 87.5% in June

Lakewood-Amedex Biotherapeutics Inc. (NASDAQ:LABT) was the recipient of a large increase in short interest in June. As of June 15th, there was short interest totaling 73,164 shares, an increase of 87.5% from the May 31st total of 39,018 shares. Based on an average trading volume of 362,400 shares, the short-interest ratio is currently 0.2 days. Currently, 10.5% of the company’s shares are short sold.

Analysts Set New Price Targets

Separately, Wall Street Zen cut shares of Lakewood-Amedex Biotherapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, May 30th.

Lakewood-Amedex Biotherapeutics Stock Down 19.3%

Lakewood-Amedex Biotherapeutics stock traded down $0.64 during mid-day trading on Thursday, hitting $2.66. The company had a trading volume of 265,834 shares, compared to its average volume of 290,699. Lakewood-Amedex Biotherapeutics has a 1 year low of $2.72 and a 1 year high of $98.20. The business has a fifty day moving average of $12.90.

About Lakewood-Amedex Biotherapeutics

We are a biotechnology company focused on leveraging unique, pioneering science to address unmet needs in the treatment of infectious diseases, improving patient outcomes, and significantly reducing the threat posed by antibiotic-resistant bacterial strains, including methicillin resistant Staphylococcus aureus (MRSA), vancomycin resistant Enterococci species (VRE), and others. Antimicrobial resistance (AMR) represents a growing global health crisis, being directly responsible for 1.27 million deaths annually and contributing to nearly 5 million deaths worldwide.